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Abstract Bone marrow metastases are formed in the late
phases of prostate cancer disease. Stem cell factor (SCF) and
granulocyte colony-stimulating factor (G-CSF) are present
in the microenvironment of the bone marrow and play a
vital role in cell biology therein. The present study was to
investigate the influence of SCF and G-CSF on stem-like
properties in prostate cancer cell lines. Upon stimulation
with SCF or G-CSF, higher levels of CD117, ABCG2, and
CD44 were observed in PC-3 and DU145 cells examined by
flow cytometry. Simultaneously, the expressions of Oct3/4
and Nanog were upregulated. Moreover, quantitative real-
time PCR verified that the increased Nanog under the stim-
ulations was mostly derived from NANOGP8. In parallel
with the increasing expressions of these proteins, higher
colony and sphere formation efficiencies were seen in these
cells in response to the cytokine stimulations. Furthermore,
a synergistic effect of SCF and G-CSF on colony and sphere
formations and ABCG2 expression was disclosed. Our
results indicate a favorable bone marrow niche for prostate
cancer cells where higher levels of cell stemness are main-
tained at least partly by the cytokines SCF and G-CSF.
Keywords SCF. G-CSF . Prostate cancer . Stem-like
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Introduction
Prostate cancer is the most common male malignancy in the
Western world. During the development of the prostate
cancer disease, malignant cells may spread to other parts
of the body to form more aggressive tumors, particularly the
metastatic bone tumor [1]. The bone marrow niche stores a
variety of cytokines and growth factors, and thus, it could be
present as “seed and soil” for the metastatic cancer cells as
has been proposed by Paget [2]. The spreading of prostate
cancer cells can take place early in the disease, and some of
the metastatic cells could alter their phenotype and hide in
the bone marrow with a relatively quiescent state or prolif-
erating at a reduced rate [3]. The recurrence and the meta-
static process of prostate cancer are also tightly linked with
the biology of a rare subpopulation of undifferentiated cells
defined as cancer stem cells (CSCs) within tumors, exhibit-
ing stem cell characteristics [4]. Data indicate that the bone
marrow niche could supply an adequate microenvironment
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for the survival/proliferation of CSCs and maintain their
stemness properties [5].
The bone marrow is the major source of hematopoi-
etic cytokines including stem cell factor (SCF) and
granulocyte colony-stimulating factor (G-CSF). SCF is
an early-acting hematopoietic cytokine that plays a con-
stitutively important role in the proliferation and surviv-
al of pluripotent progenitor cells, together with its
receptor CD117 [6]. The G-CSF receptor is present on
precursor cells of various hematopoietic cells in the
bone marrow, and initiates proliferation and differentia-
tion into mature granulocytes, in response to stimulation
by G-CSF [7]. SCF has also been identified in the
supernatant of some non-hematopoietic tumor cell lines
including breast and small cell lung carcinoma cell
lines, suggesting cell growth stimulated by autocrine
production of SCF in CD117 receptor-bearing tumor
cells [8]. The serum level of SCF is significantly in-
creased in lung cancer patients [9]. The data from
Wiesner et al. show that prostate cancer cells could
release SCF to the extracellular milieu and also indicate
that the SCF–CD117 signaling system has a potential
contribution to prostate cancer bone metastasis [10].
Presence of G-CSF and its receptor has been demon-
strated in cancer cells such as head and neck, bladder,
and ovarian cancer cells and has been associated with the
growth of these tumor cells [11–13]. G-CSF productions by
lung [14] and bladder [15] cancer cells have been reported to
be associated with an invasive behavior of these cancer cells.
Matsuoka et al. reported a case of prostate cancer cells to
produce G-SCF by immunohistochemical analyses, indicating
its prognostic implications in prostate cancer outcome [16].
The combination of SCF and G-CSF has been demon-
strated to have a synergistic effect on the increase of prolif-
eration, differentiation, and survival of hematopoietic cells
[17], and they are crucial factors in long-term culture of
human primitive hematopoietic cells in vitro [18]. However,
the combinational influence of SCF and G-CSF on prostate
cancer cells has not been fully elucidated. Therefore, we
investigated the effect of SCF and G-CSF on the stem-like
properties in the prostate cancer cell lines PC-3 and DU145
and also studied whether a synergistic effect of these cyto-
kines could be discovered. In this study, we found that
either SCF or G-CSF could upregulate the expressions of
stemness-related factors including CD117, ABCG2, CD44,
Oct3/4, and Nanog. Even higher levels of CD117, ABCG2,
and Oct3/4 were observed in the cells stimulated by combi-
national application of SCF and G-CSF. Furthermore, the
upregulation of Nanog upon stimulation by these cytokines
was proved to be mainly derived from the NANOGP8. In
addition, SCF and G-CSF could significantly, synergistical-
ly increase the capacities of colony formation and sphere
formation in these cells.
Materials and methods
Cell culture and treatment
Human prostate cancer cell lines PC-3 and DU145 were
purchased from American Type Culture Collection (USA).
Cells were maintained in an RPMI 1640 medium (Invitro-
gen) supplemented with 10% fetal bovine serum, 100 units/
mL penicillin, 100 μg/mL streptomycin at 37°C in a humid-
ified incubator of 5% CO2. Recombinant human SCF and
recombinant human G-CSF were purchased from Invitro-
gen. The media were removed and replaced with Dulbecco’s
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-
12, Invitrogen) media overnight prior to treatment with/
without SCF (100 ng/mL), G-CSF (10 ng/mL), or in com-
bination for further analyses in both cell lines, according to
the previous study [19].
Flow cytometry analyses
The PC-3 and DU145 cells were starved in a serum-free
DMEM/F-12 medium overnight and then added with SCF,
G-CSF, or a combination of these two cytokines for 24 or
48 h before the surface markers CD117, ABCG2, and CD44
expressions were evaluated by flow cytometry. Anti-CD117
monoclonal antibody directly conjugated with phycoerythrin
(PE), anti-ABCG2 monoclonal antibody directly conjugated
with PE, and anti-CD44 monoclonal antibody directly conju-
gated with allophycocyanin (APC) were obtained from BD
Pharmingen Company. The antibodies were used at optimized
dilutions, and cells were incubated for 30 min on ice in the
dark. PE Mouse IgG2b (BD Pharmingen) and APC Mouse
IgG2b (BD Pharmingen) isotype controls were used as nega-
tive controls. Viable and single cells were gated for each
sample and analyzed on a flow cytometer (Becton Dickinson,
San Jose, CA, USA).
Immunoblotting
After a 48-h treatment with SCF, G-CSF, or in combination
for cells, whole cell extracts were dissolved by a RIPA
buffer (25 mM Tris-HCl pH 7.6, 100 mM NaCl, 1%
NP40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS); Thermo Scientific Pierce, Germany), with
protease inhibitors (0.1 μM aprotinin, 1.0 mM PMSF,
1 μM leupeptin, 1 μM pepstatin) added immediately before
use. After centrifugation at 15,000 rpm for 15 min at 4°C,
total protein concentrations were measured with a Bio-Rad
protein assay according to the manufacturer’s instruction.
The samples were heated with a benchtop heater (Model
111002, Boekel Scientific, USA) at 100°C for 10 min in a
SDS-loading buffer (500 mM Tris-HCl pH 6.8, 10% glyc-
erol, 2% SDS, 0.6 M DTT, 0.05% bromophenol blue). Then,
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an equal amount of protein per sample was separated by
SDS-polyacrylamide gel electrophoresis, transferred to a
polyvinylidene difluoride transfer membrane (BIO-RAD,
USA), and blocked with 5% nonfat dry milk in Tris-
buffered saline–Tween (TBST) for 2 h at room temper-
ature. The primary antibodies diluted in TBST/5% milk
were incubated overnight at 4°C before further second-
ary antibody incubation. The optimized antibody con-
centrations used in this study are: Oct3/4, MAB1759,
1 μg/mL; Nanog, AF1997, 1 μg/mL; and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), AF5718,
0.2 μg/mL. All the antibodies were purchased from R&D.
The corresponding secondary HRP-conjugated antibodies
were incubated for 1 h at room temperature, and immunocom-
plexes were visualized using enhanced chemiluminescence
(GE Healthcare, UK).
Quantitative real-time PCR
Total RNA of cells was extracted using the RNeasy Kit
(Qiagen, CA, USA) according to the manufacturer's instruc-
tion. RNA sample concentrations were quantified using a
spectrophotometer (Nanodrop ND-1000, USA) at OD 260/
280. Complementary DNA was subsequently synthesized
from 5 μg total RNA using the Multiscribe reverse tran-
scriptase (Applied Biosystems, Foster City, CA, USA). The
conditions for reverse transcription were: 25°C for 10 min,
37°C for 12 min, 85°C for 5 min, followed by holding at 4°C.
The mRNA expressions of NANOG1, NANOGP8, and
GAPDH were measured by quantitative real-time PCR using
a Taqman ABI 7900 Sequence Detector System
(Applied Biosystems) according to the published literature
[20]. The primers and probes for the detection of NANOG1
and NANOGP8 are the following:
NANOG1: forward primer-5′-CGCCCTGCCTAGA
AAAGACATTT-3′,
NANOG1 : reverse primer-5 ′-AGAAGCCGTC
TCTGGCTATAGATAA-3′,
NANOG1: probe-CTGCTAAGGACAACATTGAT;





All the primers and probes labeled with FAM-MGB were
obtained from Applied Biosystems. The GAPDH quantita-
tive RT-PCR kit (4352934E, Applied Biosystems) was used
as an internal control, and the Ct values of the cells without
cytokine treatment were used as calibrators for evaluating
NANOG1 and NANOGP8 expression levels in response to
cytokine stimulation.
Colony formation assay
Single cells (400 cells/well) were planted in six-well plates
for overnight incubation to allow for cell attachment. The
media were replaced with DMEM/F-12 (Invitrogen) for 24 h
before SCF (100 ng/mL), G-CSF (10 ng/mL), or both of
these cytokines was added in the culture for 10 days. The
cells were fixed with 4% buffered formalin for 15 min and
then stained with 1% crystal violet for 30 min. The plates
were gently washed with PBS and dried before microscopic
colony evaluation. Cell cluster with more than 30 cells was
considered as a colony. Colony formation efficiency was
evaluated as follows:
Colony formation efficiency ¼ colonies=input cells 100%:
Sphere formation assay
The sphere formation assay was performed based on the
previously described method [21]. Single cells were seeded
at a density of 500 cells/well in ultralow attachment six-well
plates (Ultralow Cluster Plates, Life Sciences). Cells were
cultivated in serum-free DMEM/F12 media (Invitrogen)
with/without SCF (100 ng/mL), G-CSF (10 ng/mL), or in
combination. More than 30 cells within a sphere was con-
sidered to be a full sphere and counted under inverse
microscopy. Sphere formation efficiency was evaluated as
follows:
Sphere formation efficiency ¼ colonies=input cells 100%:
Statistical analyses
All the experiments were performed at least three times.
Statistical analyses were performed using Student’s t test
(P<0.05 was considered a statistical significance). Data are
shown as mean±SD, and SPSS software (version 16.0) was
used for data analysis.
Results
Synergistic effect of SCF and G-CSF on stem-like
phenotype
CD117, ABCG2, and CD44 have been described as prostate
CSC markers based on clinical investigations and in vitro
studies of prostate cancer cell lines [22–24]. Therefore,
these surface markers were evaluated by flow cytometry in
the PC-3 and DU145 cells with/without SCF or/and G-CSF
treatment. As shown in Fig. 1a, CD117 was expressed in
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both cell lines, and its expression level was significantly
upregulated by SCF. Compared to the blank controls, 24 h
of stimulation with these cytokines resulted in the following
upregulation rates for CD117 expression: there were 4.3-
fold, 1.6-fold, and 4.9-fold increases in the PC-3 cells stim-
ulated by SCF, G-CSF, and in combination, respectively;
there were 9.1-fold, 5.7-fold, and 10.7-fold increases in the
DU145 cells stimulated by SCF, G-CSF, and in combina-
tion, respectively (Fig. 1b). After 48 h of stimulation, the
upregulation rates for the CD117 expression were as fol-
lows: 5.1-fold with SCF, 2.8-fold with G-CSF, and 5.2-fold
increases with both cytokines in the PC-3 cells; 18.5-fold
with SCF, 16.6-fold with G-CSF, and 21.7-fold increases
with both cytokines in the DU145 cells, indicating a time-
dependent induction of the CD117 expression in these cells
(Fig. 1b).
Higher levels of ABCG2 expression were identified in
the PC-3 cells cultivated with either SCF (1.7-fold increase
for 24 h and 2.3-fold increase for 48 h) or G-CSF (1.6-fold
and 1.7-fold increases for the cells in 24- and 48-h
cultivations, respectively) (Fig. 2a, b). An even higher
expression of ABCG2 was observed in the cells treated
by combinational application of these two cytokines:
3.4-fold and 3.5-fold increases for the cells in 24- and 48-
h cultivations, respectively (Fig. 2b). Similarly, a significant
increase of ABCG2 expression upon stimulation with
these cytokines was also observed in the DU145 cells
(Fig. 2a). SCF treatment resulted in 21.9-fold and 22.2-
fold increases for the cells when cultivated for 24 and
48 h, respectively. G-CSF treatment demonstrated 23.7-
fold and 24.0-fold increases for the cells in 24- and
48-h cultivations, respectively. Combinational application
of these two cytokines resulted in 32.2-fold and 34.6-fold
increases for the cells in 24- and 48-h cultivations, respective-
ly (Fig. 2b), suggesting a synergistic effect of these two
cytokines on the ABCG2 expression in these cell lines.
Figure 3a shows about 50% CD44 positivity in the PC-3
cells and 55% CD44 positivity in the DU145 cells. Com-
paratively, the CD44 expression was upregulated at higher
levels after cytokine stimulation. Application of SCF in the
PC-3 cells could result in a 1.6-fold increase of CD44
expression for the cells either in a 24- or 48-h cultivation,
and use of SCF in the DU145 cells resulted in a 1.5-fold
increase of CD44 expression for the cells in either a 24- or
48-h cultivation. There were 1.5-fold and 1.6-fold increases
in CD44 expression in the cells cultivated with G-CSF for
24 and 48 h, respectively (Fig. 3b). Combinational applica-
tion of both SCF and G-CSF resulted in about 1.7-fold
increase in CD44 expression in the PC-3 cells cultivated
for 24 and 48 h. In DU145 cells, the upregulated CD44
expression was also observed in the cells treated with SCF
and G-CSF. There was about 1.4-fold CD44 increase in
CD44 expression in the cells treated with either SCF or G-
CSF. There was a 1.5-fold increase in CD44 expression in
the cells treated with a combinational application of these
cytokines (Fig. 3b).
Effect of SCF and G-CSF on stemness marker expressions
The stemness factors Oct3/4 and Nanog were examined by
immunoblotting after cultivation of the PC-3 and DU145
cell lines in the presence or absence of SCF, G-CSF, or both
in combination. Oct3/4 and Nanog expressions were upre-
gulated in both cell lines stimulated by SCF, G-CSF, or both
cytokines in combination (Fig. 4a). Furthermore, quantita-
tive real-time PCR was used to discriminate whether
the upregulated Nanog was derived from NANOG1 or
NANOGP8. NANOG1 expression showed almost no re-
sponse to the stimulation of these cytokines. However, the
NANOGP8 expression was dramatically induced by either
SCF (2.7-fold increase in PC-3 cells and 2.8-fold increase in
DU145 cells) or G-CSF (2.1-fold increase in PC-3 cells and
2.6-fold increase in DU145 cells), and even higher levels of
expressions were detected by the combinational treatment of
these two cytokines (3.4-fold increase in PC-3 cells and 4.4-
fold increase in DU145 cells), which was consistent with the
induced Nanog protein expression in both cell lines
(Fig. 4b).
Synergistic effect of SCF and G-CSF on clonogenicity
The capacity of clonogenic property was investigated by
colony formation and sphere formation assays in these cell
lines treated with SCF, G-CSF, or in combination of these
cytokines. More colonies were observed in the cells stimu-
lated by either SCF or G-CSF, and even more colonies were
seen in the combinational application of these two cytokines
(Fig. 5a). Statistical analyses confirmed a significant in-
crease of colony formation efficiency in the cells treated
with either SCF or G-CSF and even higher efficiency in the
cells treated with both cytokines in both cell lines (Fig. 5b).
Both PC-3 and DU145 cells could form spheres at ultralow
attachment plates albeit with low efficiency of sphere for-
mation (Fig. 5c). As shown in Fig. 5d, higher sphere forma-
tion efficiency was seen in the cells treated with either SCF
or G-CSF, and even higher sphere formation efficiency was
Fig. 1 CD117 expression by flow cytometry. a Representative images
of CD117 expressions by flow cytometry in PC-3 and DU145 cell lines
by stimulation with cytokines (SCF, G-CSF, or both cytokines for a 24-
or 48-h cultivation). Mouse nonimmune IgG2b labeled with PE was
used as isotype control corresponding to the antibody of CD117
conjugated with PE (top panel). b Histograms (left panels) and the
corresponding tables (right panels) show increasing CD117 expres-
sions in the cells treated with the cytokines for both cell lines. (Asterisk
means P<0.05 vs. blank control; double asterisks means P<0.01 vs.
blank control)
R
Tumor Biol. (2012) 33:967–978 971
972 Tumor Biol. (2012) 33:967–978
observed in the cells with the combinational treatment of
these two cytokines compared with the blank controls in
both cell lines. The results of colony formation and sphere
formation suggest a synergistic effect of these two cytokines
on the clonogenicity of cells.
Discussion
Prostate cancer has an affinity to metastasize to the bone
marrow, where cytokines like SCF and G-CSF may act on
the cell stemness of tumor cells directly or indirectly in
autocrine and/or paracrine mechanisms. It is believed that
the metastatic cells are prone to be resistant to conventional
chemotherapy and radiotherapy, a feature associated with
stem-like cell properties in the bone marrow niche. There-
fore, we examined how these two cytokines influenced
stem-like properties in the prostate cancer cell lines PC-3
and DU145. In our current study, we found that SCF and G-
CSF induced the expressions of several surface markers and
stemness factors, in addition to the colony and sphere for-
mation potentials in both cell lines, indicating greater stem-
like properties of cells in response to SCF and G-CSF.
In accordance with a previous study [25], we found that
CD117, the SCF primary receptor, was expressed in prostate
cancer cell lines PC-3 and DU145. Increased expressions of
SCF and CD117 have been found in several human malig-
nancies including gastrointestinal stromal tumors, acute my-
eloid leukemia, and gliomas [26]. As expected, our results
further showed that the levels of CD117 expression could be
induced by SCF stimulation in prostate cancer cells. An
increased frequency of CD117 expression in the epithelial
compartment of prostate cancer bone metastasis, compared
to benign prostatic hyperplasia and primary prostate can-
cers, has been reported in human specimens by immunohis-
tochemical analyses, suggesting an association between
elevated SCF-CD117 signaling and bone metastasis in pros-
tate cancer [10]. SCF, upon binding to its receptor CD117,
causes receptor dimerization and activation of tyrosine res-
idues, and signals are transmitted to downstream pathway
[27]. The proliferation and invasion of tumor including
pancreatic and prostatic cancers could be enhanced through
this signaling pathway [10, 28]. In addition, we found that
G-CSF also induced subpopulation of CD117 positive cells,
whereas the expression level was lower than that induced by
SCF or in combinational treatments in these cells, suggest-
ing that SCF plays a major role in the induction of CD117
expression in prostate cancer cells.
The bone marrow is the major source of hematopoietic
cytokines including SCF and G-CSF, and this microenvi-
ronment is believed to offer protection to the cancer cells in
escaping from chemotherapeutic agents. ABCG2 has been
widely studied and proven to be associated with multidrug
resistance. Since CSCs have been believed to display in-
creasing resistance to conventional therapy, compared to
more differentiated tumor cells comprising the majority of
mass tumor, the ABCG2 protein is also applied as a marker
for the identification of cancer stem-like cells [29]. In our
current study, ABCG2 could be significantly induced by
either SCF or G-CSF, and these cytokines showed a syner-
gistic effect on the induction of this protein expression in the
prostate cancer cell lines. The upregulation of ABCG2 by
these cytokines may explain, at least partly, why bone
marrow metastatic prostate cancer cells are chemotherapy/
radiotherapy-resistant.
The data from Patrawala et al. have shown that CD44+
prostate cancer cells possess inherently greater stem-like
characteristics such as being more tumorigenic and meta-
static than the corresponding CD44− cells, indicating their
association with stem/progenitor cells of prostate cancer
[30]. In our present study, we found that CD44 was highly
expressed in the PC-3 and DU145 prostate cancer cell lines,
and its expression was upregulated by the stimulation of
SCF, G-CSF, or in combination of these cytokines. CD44
has been identified as a putative prostate CSC marker,
selectively expressed in human prostate cancer cells with
neuroendocrine features [31], and such CD44+ cells were
suggested to be resistant to hormonal therapy, favoring
tumor recurrence following androgen ablation [32, 33]. In
line with this finding, the inductive effect of SCF and G-
CSF on the expressions of CD117, ABCG2, and CD44 in
prostate cancer cells may indicate a role of these cytokines
in enriching CSC cells of prostate cancer cells with a feature
of drug resistance in a special niche like the bone marrow.
The stemness factors Oct3/4 and Nanog play an impor-
tant role in maintaining the self-renewal of embryonic stem
cells and primordial germ cells. They are also identified in
prostate tumor cell lines as well as in primary prostate tumor
tissues [34, 35]. In line with previous reports, we found that
Oct3/4 and Nanog were expressed in the prostate cancer cell
lines PC-3 and DU145. Furthermore, we also found that
these stemness factors could be induced by SCF, G-CSF, or
combinational stimulation in both cell lines. Sotomayor et
al. have found that Oct3/4 expression is overexpressed in
prostate cancers with high Gleason scores [35]. It has been
reported that Oct3/4 is increasingly expressed in drug-
Fig. 2 ABCG2 expression by flow cytometry. a Representative
images of ABCG2 expressions by flow cytometry in both cell lines
with the same treatments as described above. Mouse nonimmune
IgG2b labeled with PE was used as isotype control corresponding to
the antibody of ABCG2 conjugated with PE. b Histograms (left panels)
and the corresponding tables (right panels) show higher expressions of
ABCG2 in both cell lines stimulated with either SCF or G-CSF and
even higher expressions in the cells treated by combinational applica-
tion of these cytokines. (Asterisk means P<0.05 vs. blank control;
double asterisks means P<0.01 vs. blank control)
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resistant prostate cancer cell lines evaluated by RT-PCR,
Western blot, and specific shRNA knock down assays
[36]. Nanog has also been reported to be expressed in higher
levels in prostate tumors than in the matched benign prostate
tissues [37], indicating an important role in maintaining
CSC characteristics and prostate cancer resistance to andro-
gen deprivation [20]. Since NANOGP8 expression has been
Fig. 3 CD44 expression by flow cytometry. a Representative images of
CD44 expressions by flow cytometry in PC-3 andDU145 cell lines with the
same treatments as described above.Mouse nonimmune IgG2b labeledwith
APC was used as isotype control corresponding to the antibody of CD44
conjugated with APC. b Histograms (left panels) and the corresponding
tables (right panels) show increasing CD44 expression by stimulation with
SCF, G-CSF, or both cytokines in both cell lines. (Asterisk means P<0.05
vs. blank control; double asterisks means P<0.01 vs. blank control)
R
Fig. 4 Oct3/4 and Nanog
expressions by immunoblotting
and NANOG1 and NANOGP8
expressions by quantitative
real-time PCR. a Immunoblot-
ting analyses show that Oct3/4
and Nanog expressions are in-
creased in the PC-3 and DU145
cell lines treated with SCF, G-
CSF, or both cytokines.
GAPDH was used as internal
loading control. b Either SCF or
G-CSF results in a higher
NANOGP8 expression, and
combinational application of
both SCF and G-CSF results in
even higher NANOGP8 expres-
sion by quantitative real-time
PCR. However, NANOG1
shows almost no response to
such cytokines
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Fig. 5 Colony formation and
sphere formation analyses. a
Representative photographs of
colony formation show more
colonies in the cells treated with
either SCF or G-CSF and even
more colonies in the cells trea-
ted with both cytokines in PC-3
and DU145 cell lines. b Histo-
grams demonstrate higher colo-
ny formation efficiency in the
cells treated with either SCF or
G-CSF and even higher colony
formation efficiency in the cells
treated with both. c Represen-
tative views of sphere formation
in PC-3 and DU145 cell lines
with/without cytokine treat-
ments. d Histograms show
higher sphere formation effi-
ciency in the cells treated with
either SCF or G-CSF and even
higher sphere formation effi-
ciency in the cells stimulated
with both SCF and G-CSF
(Asterisk means P<0.05 vs.
blank control; double asterisks
means P<0.01 vs. blank
control)
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found in cancer [38] and previous studies indicated its
important role in maintaining cancer stem-like properties
in prostate cancer cells [20, 37], further experiments were
performed to distinguish the increased Nanog expression
from NANOG1 or NANOGP8. In line with these reports,
we repeatedly showed that NANOGP8 was predominantly
upregulated by either SCF or G-CSF, and even higher ex-
pression was obtained by combinational stimulation of these
two cytokines in both cell lines.
SCF and G-CSF are not only available for regulation of
growth and differentiation for hematopoietic progenitor
cells, but also stimulate the proliferation/invasion of somatic
cancer cells such as head and neck carcinoma, pancreatic
cancer, colorectal cancer, and bladder and prostatic carcino-
ma cells [10, 27, 28, 39, 40]. SCF serves as a survival factor
to promote cellular proliferation or clonogenic growth in
lung cancer [41, 42] and prostate cancer [25]. Moreover,
SCF–CD117 autocrine signaling could stimulate prolifera-
tion of lung CSCs isolated from human non-small cell lung
cancer cell lines in suspension growth [43]. In the present
study, SCF also showed a greater induction of colonies and
spheres in prostate cancer cells, indicating that the capacity
of colony and sphere formations may be associated with the
SCF–CD117 axis, based on the upregulation of CD117 by
SCF as well. It has been reported that G-CSF could be
secreted by PC-3, but not by DU145; however, the receptors
of G-CSF were found to be expressed in both PC-3 and
DU145 cell lines [44]. In addition, the same report has
shown that G-CSF, together with macrophage colony-
stimulating factor and IL-3, stimulates the activity of prolif-
eration in the prostate cancer cell line PC-3. Importantly, a
similar result was also found in our present study that more
colonies and spheres were observed in both cell lines treated
with G-CSF alone.
SCF has a synergistic effect with G-CSF for long-term
culture of human primitive hematopoietic cells [18] and
expansion of human hematopoietic stem/progenitor cells
for transplantation in vitro [45, 46]. Similar to these find-
ings, we discovered that there was a synergistic effect of
SCF and G-CSF on the induction of colony and sphere
formation potentials in prostate cancer cell lines.
Collectively, our data may partly explain why bone mar-
row metastatic prostate cancer cells are resistant to chemo-
therapy/radiotherapy, for which much is still unknown in
special consideration how metastatic prostate cancer cells in
the bone marrow can be dormant for years or decades.
Although an increasing potential of sphere and colony for-
mations and high levels of ABCG2 expression influenced
by these cytokines may account for their higher stemness in
one way, it is still not clear how these cells can be dormant
in this niche for a longer period. There must be other
important factors for the cells kept dormant in addition to
these cytokines in the upregulation of cell stemness. We
speculate that at least another factor, TGF-beta, should be
explored in order to further characterize the possibility of
cell dormancy.
In summary, our results show that SCF and G-CSF could
synergistically upregulate the expressions of CSC markers
CD117, CD44, and ABCG2, and induce the expressions of
transcription factors Oct3/4 and Nanog in prostate cancer
cell lines PC-3 and DU145. In parallel with such increasing
expressions, there was an increasing potential of colony and
sphere formations in these cells, suggesting a role of stem-
ness induction of these cytokines.
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